Sanofi: new proceedings for Praluent patent.
(CercleFinance.com) - Sanofi has announced that the federal court of appeal of the United States has ordered a new trial and has cancelled the permanent injunction in the ongoing dispute relating to the Praluent patent (alirocumab).
This decision means that Sanofi and Regeneron will continue to market, sell, and produce the injectable product Praluent (alirocumab) in the US.
Because of the erroneous exclusion of certain evidence, the court found that the case was incomplete and concluded at that time here that Sanofi and Regeneron were not entitled to a judgment from a legal point of view (JMOL) on issues of written description and authorisation.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This decision means that Sanofi and Regeneron will continue to market, sell, and produce the injectable product Praluent (alirocumab) in the US.
Because of the erroneous exclusion of certain evidence, the court found that the case was incomplete and concluded at that time here that Sanofi and Regeneron were not entitled to a judgment from a legal point of view (JMOL) on issues of written description and authorisation.
Copyright (c) 2017 CercleFinance.com. All rights reserved.